|
1
|
World Health Organization, . Global breast
cancer initiative implementation framework: assessing,
strengthening and scaling up of services for the early detection
and management of breast cancer: executive summary. World Health
Organization. 2023.
|
|
2
|
Xia C, Dong X, Li H, Cao M, Sun D, He S,
Yang F, Yan X, Zhang S, Li N and Chen W: Cancer statistics in China
and United States, 2022: Profiles, trends, and determinants. Chin
Med J (Engl). 135:584–590. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Britt KL, Cuzick J and Phillips KA: Key
steps for effective breast cancer prevention. Nat Rev Cancer.
20:417–436. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Allemani C, Matsuda T, Di Carlo V,
Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ,
Estève J, et al: Global surveillance of trends in cancer survival
2000-14 (CONCORD-3): Analysis of individual records for 37 513 025
patients diagnosed with one of 18 cancers from 322 population-based
registries in 71 countries. Lancet. 391:1023–1075. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kerr AJ, Dodwell D, McGale P, Holt F,
Duane F, Mannu G, Darby SC and Taylor CW: Adjuvant and neoadjuvant
breast cancer treatments: A systematic review of their effects on
mortality. Cancer Treat Rev. 105:1023752022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Anampa J, Makower D and Sparano JA:
Progress in adjuvant chemotherapy for breast cancer: An overview.
BMC Med. 13:1952015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Frank D and Vince JE: Pyroptosis versus
necroptosis: Similarities, differences, and crosstalk. Cell Death
Differ. 26:99–114. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shi J, Gao W and Shao F: Pyroptosis:
Gasdermin-mediated programmed necrotic cell death. Trends Biochem
Sci. 42:245–254. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kovacs SB and Miao EA: Gasdermins:
Effectors of pyroptosis. Trends Cell Biol. 27:673–684. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Du T, Gao J, Li P, Wang Y, Qi Q, Liu X, Li
J, Wang C and Du L: Pyroptosis, metabolism, and tumor immune
microenvironment. Clin Transl Med. 11:e4922021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu X, Xia S, Zhang Z, Wu H and Lieberman
J: Channelling inflammation: Gasdermins in physiology and disease.
Nat Rev Drug Discov. 20:384–405. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ding J, Wang K, Liu W, She Y, Sun Q, Shi
J, Sun H, Wang DC and Shao F: Pore-forming activity and structural
autoinhibition of the gasdermin family. Nature. 535:111–116. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rao Z, Zhu Y, Yang P, Chen Z, Xia Y, Qiao
C, Liu W, Deng H, Li J, Ning P and Wang Z: Pyroptosis in
inflammatory diseases and cancer. Theranostics. 12:4310–4329. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang Y, Gao W, Shi X, Ding J, Liu W, He H,
Wang K and Shao F: Chemotherapy drugs induce pyroptosis through
caspase-3 cleavage of a gasdermin. Nature. 547:99–103. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rogers C, Fernandes-Alnemri T, Mayes L,
Alnemri D, Cingolani G and Alnemri ES: Cleavage of DFNA5 by
caspase-3 during apoptosis mediates progression to secondary
necrotic/pyroptotic cell death. Nat Commun. 8:141282017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xia X, Wang X, Cheng Z, Qin W, Lei L,
Jiang J and Hu J: The role of pyroptosis in cancer: Pro-cancer or
pro-‘host’? Cell Death Dis. 10:6502019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen L, Weng B, Li H, Wang H, Li Q, Wei X,
Deng H, Wang S, Jiang C, Lin R and Wu J: A thiopyran derivative
with low murine toxicity with therapeutic potential on lung cancer
acting through a NF-kappaB mediated apoptosis-to-pyroptosis switch.
Apoptosis. 24:74–82. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou CB and Fang JY: The role of
pyroptosis in gastrointestinal cancer and immune responses to
intestinal microbial infection. Biochim Biophys Acta Rev Cancer.
1872:1–10. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zeng H, Yang H, Song Y, Fang D, Chen L,
Zhao Z, Wang C and Xie S: Transcriptional inhibition by CDK7/9
inhibitor SNS-032 suppresses tumor growth and metastasis in
esophageal squamous cell carcinoma. Cell Death Dis. 12:10482021.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang Z, Zhang Y, Xia S, Kong Q, Li S, Liu
X, Junqueira C, Meza-Sosa KF, Mok TMY, Ansara J, et al: Gasdermin E
suppresses tumour growth by activating anti-tumour immunity.
Nature. 579:415–420. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Thompson DA and Weigel RJ:
Characterization of a gene that is inversely correlated with
estrogen receptor expression (ICERE-1) in breast carcinomas. Eur J
Biochem. 252:169–177. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Akino K, Toyota M, Suzuki H, Imai T,
Maruyama R, Kusano M, Nishikawa N, Watanabe Y, Sasaki Y, Abe T, et
al: Identification of DFNA5 as a target of epigenetic inactivation
in gastric cancer. Cancer Sci. 98:88–95. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim MS, Chang X, Yamashita K, Nagpal JK,
Baek JH, Wu G, Trink B, Ratovitski EA, Mori M and Sidransky D:
Aberrant promoter methylation and tumor suppressive activity of the
DFNA5 gene in colorectal carcinoma. Oncogene. 27:3624–3634. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen R, Wierda WG, Chubb S, Hawtin RE, Fox
JA, Keating MJ, Gandhi V and Plunkett W: Mechanism of action of
SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic
lymphocytic leukemia. Blood. 113:4637–4645. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang J, Liu S, Ye Q and Pan J:
Transcriptional inhibition by CDK7/9 inhibitor SNS-032 abrogates
oncogene addiction and reduces liver metastasis in uveal melanoma.
Mol Cancer. 18:1402019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu Y, Chen C, Sun X, Shi X, Jin B, Ding K,
Yeung SC and Pan J: Cyclin-dependent kinase 7/9 inhibitor SNS-032
abrogates FIP1-like-1 platelet-derived growth factor receptor alpha
and bcr-abl oncogene addiction in malignant hematologic cells. Clin
Cancer Res. 18:1966–1978. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Meng H, Jin Y, Liu H, You L, Yang C, Yang
X and Qian W: SNS-032 inhibits mTORC1/mTORC2 activity in acute
myeloid leukemia cells and has synergistic activity with perifosine
against Akt. J Hematol Oncol. 6:182013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kang MA, Kim W, Jo HR, Shin YJ, Kim MH and
Jeong JH: Anticancer and radiosensitizing effects of the
cyclin-dependent kinase inhibitors, AT7519 and SNS-032, on cervical
cancer. Int J Oncol. 53:703–712. 2018.PubMed/NCBI
|
|
29
|
Kodym E, Kodym R, Reis AE, Habib AA, Story
MD and Saha D: The small-molecule CDK inhibitor, SNS-032, enhances
cellular radiosensitivity in quiescent and hypoxic non-small cell
lung cancer cells. Lung Cancer. 66:37–47. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Heath EI, Bible K, Martell RE, Adelman DC
and Lorusso PM: A phase 1 study of SNS-032 (formerly BMS-387032), a
potent inhibitor of cyclin-dependent kinases 2, 7 and 9
administered as a single oral dose and weekly infusion in patients
with metastatic refractory solid tumors. Invest New Drugs.
26:59–65. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tong WG, Chen R, Plunkett W, Siegel D,
Sinha R, Harvey RD, Badros AZ, Popplewell L, Coutre S and Fox JA:
Phase I and pharmacologic study of SNS-032, a potent and selective
Cdk2, 7, and 9 inhibitor, in patients with advanced chronic
lymphocytic leukemia and multiple myeloma. J Clin Oncol.
28:3015–3022. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xie G, Tang H, Wu S, Chen J, Liu J and
Liao C: The cyclin-dependent kinase inhibitor SNS-032 induces
apoptosis in breast cancer cells via depletion of Mcl-1 and
X-linked inhibitor of apoptosis protein and displays antitumor
activity in vivo. Int J Oncol. 45:804–812. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zeng H, Yang H, Song Y, Fang D, Chen L,
Zhao Z, Wang C and Xie S: Transcriptional inhibition by CDK7/9
inhibitor SNS-032 suppresses tumor growth and metastasis in
esophageal squamous cell carcinoma. Cell Death Dis. 12:10482021.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Miao EA, Rajan JV and Aderem A:
Caspase-1-induced pyroptotic cell death. Immunol Rev. 243:206–214.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ai Y, Meng Y, Yan B, Zhou Q and Wang X:
The biochemical pathways of apoptotic, necroptotic, pyroptotic, and
ferroptotic cell death. Mol Cell. 84:170–179. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kesavardhana S, Malireddi RKS and
Kanneganti TD: Caspases in cell death, inflammation, and
pyroptosis. Annu Rev Immunol. 38:567–595. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Marino G, Niso-Santano M, Baehrecke EH and
Kroemer G: Self-consumption: The interplay of autophagy and
apoptosis. Nat Rev Mol Cell Biol. 15:81–94. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang B, Li H, Yang R, Zhou S and Zou S:
Decitabine inhibits the cell growth of cholangiocarcinoma in
cultured cell lines and mouse xenografts. Oncol Lett. 8:1919–1924.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mi D, Li J, Wang R, Li Y, Zou L, Sun C,
Yan S, Yang H, Zhao M and Shi S: Postsurgical wound management and
prevention of triple-negative breast cancer recurrence with a
pryoptosis-inducing, photopolymerizable hydrogel. J Control
Release. 356:205–218. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Parua PK and Fisher RP: Dissecting the Pol
II transcription cycle and derailing cancer with CDK inhibitors.
Nat Chem Biol. 16:716–724. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Swaffer MP, Jones AW, Flynn HR, Snijders
AP and Nurse P: CDK substrate phosphorylation and ordering the cell
cycle. Cell. 167:1750–1761. e17162016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yang F, Bettadapura SN, Smeltzer MS, Zhu H
and Wang S: Pyroptosis and pyroptosis-inducing cancer drugs. Acta
Pharmacol Sin. 43:2462–2473. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen W, Yang KB, Zhang YZ, Lin ZS, Chen
JW, Qi SF, Wu CF, Feng GK, Yang DJ, Chen M, et al: Synthetic
lethality of combined ULK1 defection and p53 restoration induce
pyroptosis by directly upregulating GSDME transcription and
cleavage activation through ROS/NLRP3 signaling. J Exp Clin Cancer
Res. 43:2482024. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Su L, Chen Y, Huang C, Wu S, Wang X, Zhao
X, Xu Q, Sun R, Kong X, Jiang X, et al: Targeting Src reactivates
pyroptosis to reverse chemoresistance in lung and pancreatic cancer
models. Sci Transl Med. 15:eabl78952023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang S, Zhang Y, Feng Y, Wu J, Hu Y, Lin
L, Xu C, Chen J, Tang Z, Tian H and Chen X: Biomineralized
two-enzyme nanoparticles regulate tumor glycometabolism inducing
tumor cell pyroptosis and robust antitumor immunotherapy. Adv
Mater. 34:e22068512022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Pan J, Li Y, Gao W, Jiang Q, Geng L, Ding
J, Li S and Li J: Transcription factor Sp1 transcriptionally
enhances GSDME expression for pyroptosis. Cell Death Dis.
15:662024. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Broz P, Pelegrin P and Shao F: The
gasdermins, a protein family executing cell death and inflammation.
Nat Rev Immunol. 20:143–157. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhang Y, Chen X, Gueydan C and Han J:
Plasma membrane changes during programmed cell deaths. Cell Res.
28:9–21. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Man SM, Karki R and Kanneganti TD:
Molecular mechanisms and functions of pyroptosis, inflammatory
caspases and inflammasomes in infectious diseases. Immunol Rev.
277:61–75. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Xie B, Liu T, Chen S, Zhang Y, He D, Shao
Q, Zhang Z and Wang C: Combination of DNA demethylation and
chemotherapy to trigger cell pyroptosis for inhalation treatment of
lung cancer. Nanoscale. 13:18608–18615. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Gong W, Fang P, Leng M and Shi Y:
Promoting GSDME expression through DNA demethylation to increase
chemosensitivity of breast cancer MCF-7/Taxol cells. PLoS One.
18:e02822442023. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Bose P, Simmons GL and Grant S:
Cyclin-dependent kinase inhibitor therapy for hematologic
malignancies. Expert Opin Investig Drugs. 22:723–738. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Bixby D and Talpaz M: Seeking the causes
and solutions to imatinib-resistance in chronic myeloid leukemia.
Leukemia. 25:7–22. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Uzhachenko RV, Bharti V, Ouyang Z, Blevins
A, Mont S, Saleh N, Lawrence HA, Shen C, Chen SC, Ayers GD, et al:
Metabolic modulation by CDK4/6 inhibitor promotes
chemokine-mediated recruitment of T cells into mammary tumors. Cell
Rep. 35:1089442021. View Article : Google Scholar : PubMed/NCBI
|
